Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 17/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 16/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10717773 | 0.87 | MAPK1 (0.55) | MAPK1ALDH1A1ALOX5RAB9ANPC1 | |
| SCHEMBL15923829 | 0.82 | FEN1 (0.70) | FEN1ALOX5AP | |
| SCHEMBL11371855 | 0.79 | NOS3 (0.50) | FEN1ALOX5APRAB9ANPC1 | |
| SCHEMBL998308 | 0.79 | FEN1 (0.59) | FEN1ALOX5APMAPK1RAB9ANPC1 | |
| SCHEMBL2322762 | 0.79 | SLC6A2 (0.49) | FEN1ALOX5APMAPK1ALDH1A1RAB9A | |
| SCHEMBL6700757 | 0.79 | PIK3CG (0.47) | FEN1ALOX5APMAPK1ALDH1A1RAB9A | |
| SCHEMBL882102 | 0.79 | FEN1 (0.46) | FEN1ALOX5AP | |
| SCHEMBL379466 | 0.79 | FEN1 (0.47) | FEN1ALOX5AP | |
| SCHEMBL9951105 | 0.79 | FEN1 (0.60) | FEN1ALOX5AP | |
| SCHEMBL29817861 | 0.78 | FEN1 (0.62) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747255-A1 | MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025018901-A1 | MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2025-01-23 | — | — | WO | disclosed |
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-03 | — | — | US | disclosed |
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-03 | — | — | US | disclosed |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-02 | — | — | US | disclosed |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-02 | — | — | US | disclosed |
| US-20190055217-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-02-21 | — | — | US | disclosed |
| US-20190055217-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-02-21 | — | — | US | disclosed |
| WO-2017178510-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017178515-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-19 | — | — | WO | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| CN-100418965-C | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2007096764-A2 | BICYCLIC HETEROARYL DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-08-30 | — | — | WO | disclosed |
| CN-1835950-A | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | OPRD1, TRPV1, OPRL1 | FEN1 4881/4885ALOX5AP 1533/4885MAPK1 3059/4885 |
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | FEN1 4741/4885ALOX5AP 3560/4885MAPK1 973/4885 |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, TRPV1, OPRL1 | FEN1 4881/4885ALOX5AP 1533/4885MAPK1 3059/4885 |
| US-20190055217-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRK1, OPRM1 | FEN1 4779/4885ALOX5AP 1243/4885MAPK1 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.